Main inclusion Criteria:

1. Male or female, at least 18 years of age at the time of informed consent

2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

3. Histologically or cytologically confirmed, locally advanced or metastatic colorectal
cancer (CRC) that is documented to be without Kirsten rat sarcoma (KRAS) or
Neuroblastoma rat sarcoma (NRAS) gene mutations (i.e. tumors must express the KRAS
and NRAS wild type (WT), exon 2, 3 and 4).

4. Failed* treatment for locally advanced or metastatic disease with first-line
combination therapy of oxaliplatin and a fluoropyrimidine, with or without
bevacizumab, during treatment or < 3 months after the last dose of first-line therapy
and within < 3 months of C1/D1.

Patients who discontinued first-line therapy due to toxicity may be enrolled provided
progression occurred < 6 months after the last dose of the first-line therapy
regimen.

or Failed* adjuvant therapy with combination therapy of oxaliplatin and a
fluoropyrimidine during treatment or within < 6 months after the last dose of
oxaliplatin and within < 6 months of C1/D1.

- Failure is defined as radiologic progression

5. Eligible for FOLFIRI

6. Measurable disease according to RECIST v1.1

Main exclusion Criteria:

1. Prior therapy with anti-EGFR antibodies, anti-EGFR small molecule inhibitors or
irinotecan (CPT-11)

2. Any antineoplastic agent (standard or investigational) within 4 weeks prior to C1/D1

3. Significant gastrointestinal abnormalities

4. Patients with a significant cardiovascular disease or condition

5. Abnormal hematologic, renal or hepatic function

Minimum Eligible Age: 18 Years

Maximum Eligible Age: N/A

Eligible Gender: Both